Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations is a research paper published in Journal of Cystic Fibrosis (2022). On theSindex it has a DataRank of 0.357. It has been cited 6 times, with 1 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0.0651
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 1 citer.
Cystic Fibrosis Foundation
Grant: WEST15A0
Cystic Fibrosis Foundation
Grant: KESSLE17AB0
Cystic Fibrosis Foundation
Grant: FLUME15A0
Cystic Fibrosis Foundation
Grant: SANDER17AB0
Cystic Fibrosis Foundation
Grant: WEST175Y
Cystic Fibrosis Foundation
Grant: HELTSH15A0
Cystic Fibrosis Foundation
Grant: FLUME17AB0
Cystic Fibrosis Foundation
Grant: SANDER14A0
Cystic Fibrosis Foundation
Grant: WEST17AB0
Cystic Fibrosis Foundation
Grant: GOSS15A0
National Institutes of Health
Grant: UL1 TR001450
National Institutes of Health
Grant: P30 DK089507
National Institutes of Health
Grant: 02781610
FWCI
0.82
Citation Percentile
0.7%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals